<div class="infobox infobox-institution">
{| class="infobox-table"
| colspan="2" class="infobox-header" | International Parkinson's Disease Genetics Consortium (IPDGC)
|-
| Founded | 2009
|-
| Type | International Research Consortium
|-
| Focus | Parkinson's disease genetics and genomics
|-
| Membership | 100+ institutions globally
|-
| Website | [pdgenetics.org](https://pdgenetics.org)
|}
</div>
<div class="infobox infobox-institution">
{| class="infobox-table"
| colspan="2" class="infobox-header" | International Parkinson's Disease Genetics Consortium (IPDGC)
|-
| Founded | 2009
|-
| Type | International Research Consortium
|-
| Focus | Parkinson's disease genetics and genomics
|-
| Membership | 100+ institutions globally
|-
| Website | [pdgenetics.org](https://pdgenetics.org)
|}
</div>
The International Parkinson's Disease Genetics Consortium (IPDGC) is a global network of researchers dedicated to identifying genetic factors that contribute to Parkinson's disease risk, progression, and therapeutic response["@global2022"]. Founded in 2009, the consortium coordinates large-scale genetic studies across diverse populations worldwide, making it one of the most influential collaborative efforts in neurodegenerative disease research.
The IPDGC has transformed our understanding of Parkinson's disease genetics through unprecedented collaboration["@ipdgc2019"]. By pooling data and samples from hundreds of researchers across dozens of countries, the consortium has identified over 100 genetic risk loci for Parkinson's disease, discovered novel disease-causing mutations, and established resources that enable precision medicine approaches for PD treatment.
The consortium's work has fundamental implications for understanding disease mechanisms, identifying therapeutic targets, and eventually developing disease-modifying therapies. Genetic discoveries provide crucial insights into the biological pathways involved in Parkinson's disease pathogenesis, including alpha-synuclein aggregation, mitochondrial dysfunction, lysosomal impairment, and neuroinflammation["@singleton2014"].
The IPDGC pursues several interconnected missions:
Discovery of Genetic Risk Factors
The consortium conducts genome-wide association studies (GWAS), whole exome sequencing (WES), and whole genome sequencing (WGS) to identify both common and rare genetic variants influencing Parkinson's disease risk. Each discovery provides potential insight into disease biology and therapeutic targets[@farrer2006].
Understanding Disease Mechanisms
By characterizing how genetic variants contribute to disease pathogenesis, IPDGC researchers elucidate the molecular mechanisms underlying Parkinson's disease. This knowledge guides drug development and helps identify promising therapeutic targets.
Enabling Precision Medicine
Genetic stratification of patients enables development of targeted therapies for specific genetic subtypes. The consortium develops and validates genetic testing approaches that can guide clinical care and clinical trial enrollment[@katz2023].
Data Sharing and Resource Development
The IPDGC maintains shared data resources that accelerate discovery by enabling researchers worldwide to analyze pooled datasets. This approach maximizes the scientific return on research investment.
The IPDGC has conducted the largest Parkinson's disease GWAS to date[@nalls2019], identifying:
Rare genetic variants with large effect sizes provide particularly powerful insights into disease biology. The IPDGC WES program has:
Comprehensive WGS enables detection of all variant types:
The Global Parkinson's Genetics Program represents the largest single initiative in PD genetics[@global2022]. This $150 million program aims to:
The consortium developed NeuroXchip, a custom genotyping array optimized for neurodegenerative disease research[@blauwendraat2020]. This specialized chip includes:
The IPDGC has contributed to characterizing genes causing familial Parkinson's disease:
SNCA (Alpha-Synuclein)
The first gene linked to hereditary Parkinson's disease[@singleton2014]. Multiplications cause autosomal dominant PD with dementia. Point mutations (A53T, A30P, E46K) cause Lewy body disease. The discovery established that alpha-synuclein aggregation is central to PD pathogenesis.
LRRK2 (Leucine-Rich Repeat Kinase 2)
The most common cause of autosomal dominant Parkinson's disease. The G2019S mutation accounts for up to 5% of PD in some populations[@schaller2015]. LRRK2 inhibitors are in clinical development.
GBA (Glucocerebrosidase)
GBA mutations represent the most significant genetic risk factor for PD identified to date[@giannoccaro2019]. Carriers have 5-6x increased risk. The link between Gaucher disease and PD established the importance of lysosomal dysfunction in PD pathogenesis.
PARKIN and PINK1
These genes cause autosomal recessive young-onset Parkinson's disease. They are critical for mitochondrial quality control (mitophagy), establishing mitochondrial dysfunction as a key PD mechanism.
ATP13A2, DNAJC13, and VPS35
Additional genes identified through IPDGC research, each revealing novel biological pathways.
The IPDGC has systematically mapped common genetic variants influencing PD risk[@pankratz2009]. Key loci include:
| Gene/Locus | Mechanism | Therapeutic Target |
|------------|-----------|-------------------|
| SNCA | Alpha-synuclein aggregation | Anti-aggregation drugs |
| LRRK2 | Kinase activity | LRRK2 inhibitors |
| GBA | Lysosomal function | Gene therapy, chaperones |
| HLA-DRA | Immune regulation | Anti-inflammatory drugs |
| MAPT | Tau pathology | Anti-tau therapies |
| GCH1 | Dopamine synthesis | DOPA supplementation |
A major IPDGC priority is understanding Parkinson's disease genetics across all populations[@global2022]. Prior to GP2, over 80% of PD genetics research involved European-ancestry subjects, missing critical insights from other populations.
African Populations
iPDGC Africa studies African cohorts to identify novel risk factors and understand the genetic architecture in these understudied populations. Founder mutations and unique risk factors are being characterized.
Ashkenazi Jewish Population
Studies in this well-characterized founder population have identified unique genetic factors and validated known risk alleles[@plot2012].
Asian Populations
Research across East Asia, South Asia, and Southeast Asia has identified both shared and population-specific risk factors. LRRK2 variants show different frequency patterns compared to European populations.
The IPDGC coordinates research through regional hubs:
| Region | Lead Institutions |
|--------|-------------------|
| North America | NIH, Mayo Clinic, Columbia University |
| Europe | Karolinska Institute, University College London |
| Asia | National University of Singapore, Tokyo University |
| Australia | University of Sydney, University of Queensland |
Funding Organizations
The IPDGC coordinates with other specialized consortia:
The consortium maintains shared data resources:
Standardized analysis pipelines enable:
The IPDGC has developed guidelines for clinical genetic testing in PD:
Genetic stratification is enabling:
The consortium has produced:
Genetic discoveries have:
The consortium supports:
The IPDGC has outlined ambitious future goals:
Expand Diversity
The consortium is preparing for: